Wells Fargo & Company Revance Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 62,930 shares of RVNC stock, worth $161,730. This represents 0.0% of its overall portfolio holdings.
Number of Shares
62,930
Previous 55,073
14.27%
Holding current value
$161,730
Previous $270,000
40.37%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding RVNC
# of Institutions
197Shares Held
81.5MCall Options Held
490KPut Options Held
128K-
Capital World Investors Los Angeles, CA13.9MShares$35.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA6.26MShares$16.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.99MShares$15.4 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.26MShares$13.5 Million1.71% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...